Estrogen receptor-negative/progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers

1997 ◽  
Vol 120 (1) ◽  
pp. 23-30 ◽  
Author(s):  
M Borras ◽  
M Lacroix ◽  
N Legros ◽  
G Leclercq
Keyword(s):  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Tumor Cells ◽  
Mammary Tumor ◽  
Biological Property ◽  
Breast Cancers ◽  
Mammary Tumor Cells ◽  
Estrogen Receptor Negative

Expression of steroids and HER2-neu receptors in breast tumors associated with BRCA1 gene mutations

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22223-e22223
Author(s):  
N. A. Zarubina ◽  
V. D. Petrova ◽  
T. V. Sinkina ◽  
S. A. Terekhova ◽  
A. F. Lazarev ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Bilateral Breast Cancer ◽  
Gene Mutations ◽  
Brca1 Gene ◽  
Breast Tumors ◽  
Breast Cancers ◽  
Breast Carcinomas ◽  
Estrogen Receptor Negative

e22223 Background: Hereditary breast carcinomas that are attributable to BRCA1 mutations have their own morphological and immunohistochemical characteristics. This study was aimed to analyze the level of expression of steroids (estrogen and progesterone) and HER2-neu receptors in BRCA1 associated breast cancer. Methods: DNA patterns from 264 patients with hereditary breast cancers (breast cancer diagnosed at the age under 40; bilateral breast cancer; combination of breast and ovarian cancers; 2 and more breast cancers in blood relatives). All the patients were residents of the Altai Territory. BRCA1 gene mutations were registered in 34 patients (12.9%): 5382insC gene mutation - in 28 patients; 300A/C - in 2 patients; 4153del - in 3 patients; 185del - in 1 patient. The frequency of the BRCA1 5382insC allele mutation was 7.3; 300A/C - 0.52; 4153del - 0.26; 185del - 0.83. Immunohistochemical characteristics of BRCA1-associated breast tumors tissue from these patients were investigated. Results: 32 BRCA1-associated breast carcinomas were estrogen receptor- negative; 1 - week positive (H-score 50–100); 1 - moderate positive (H- score 100–200). 33 BRCA1-associated breast carcinomas were progesterone receptor- negative; 1 - positive (H-score 200 and more). HER2-negative were 31 BRCA1-associated breast carcinomas; 2 were week positive (HER2-neu +); 1 - was moderate positive (HER2-neu ++). Conclusion: BRCA1-associated beast carcinomas have been found to be more frequently estrogen receptor-, progesterone receptor-, and HER2- negative. These data show that hereditary breast cancer associated with BRCA1 gene mutations poses poor prognosis. No significant financial relationships to disclose.

Increased wound-response revealed by proteomics of estrogen receptor-negative breast cancers

2008 ◽  
Vol 68 (S 01) ◽  
Author(s):  
H Neubauer ◽  
K Sotlar ◽  
D Wallwiener ◽  
MA Cahill ◽  
E Solomayer ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Wound Response ◽  
Breast Cancers ◽  
Estrogen Receptor Negative

Breast cancers negative for estrogen receptor but positive for progesterone receptor, a true entity?

1987 ◽  
Vol 5 (4) ◽  
pp. 662-666 ◽  
Author(s):  
D T Kiang ◽  
R Kollander
Keyword(s):  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Staining Method ◽  
Binding Assay ◽  
Assay Method ◽  
Breast Cancers ◽  
Antibody Method ◽  
Steroid Binding ◽  
Rare Group ◽  
Er Status

By the conventional steroid-binding assay method for receptor, 3% of 1,095 primary breast cancers (or 10.6% of 263 premenopausal tumors) were classified as negative for estrogen receptor (ER), but positive for progesterone receptor (PR). The true ER status in this rare group of tumors was further investigated by the enzyme-immunoassay (EIA) or immunocytochemical (ICA) staining method using monoclonal antibodies H222 and D547. Immunoreactive ER was present in nine ER-/PR+ tumors studied, whereas it was not detectable in nine age-matched ER-/PR- tumors. Immunoreactive ER was also present in 24 ER+ breast cancers studied, and was particularly higher in tumors that were PR+. Measurement of immunoreactive ER by monoclonal antibody method provides certain advantages over the conventional dextran-coated charcoal (DCC) method, especially in ER-/PR+ tumors.

scholarly journals Binding Sites of Droloxifene in the Cytosol of 7,12-Dimethylbenz[α]anthracene-induced Rat Mammary Tumor Cells

1994 ◽  
Vol 85 (6) ◽  
pp. 639-644
Author(s):  
Ikuo Kawamura ◽  
Elizabeth Lacey ◽  
Yoshio Tanaka ◽  
Fusako Nishigaki ◽  
Toshitaka Manda ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Mammary Tumor ◽  
Binding Sites ◽  
Mammary Tumor Cells ◽  
Rat Mammary Tumor

scholarly journals Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients

Cancer ◽  
1993 ◽  
Vol 72 (7) ◽  
pp. 2291-2292 ◽  
Author(s):  
Vincent F. Guinee ◽  
Kenneth R. Hess ◽  
Richard M. Elledge ◽  
Gregory Langone ◽  
Daniel R. Ciocca
Keyword(s):  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Breast Cancers ◽  
Her 2
Sign in / Sign up

Export Citation Format

Share Document